Welcome to our dedicated page for Nrx Pharmaceuticals news (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on Nrx Pharmaceuticals stock.
NRx Pharmaceuticals, Inc. reports clinical, regulatory, manufacturing, and subsidiary developments for a biopharmaceutical business focused on neuroplastic therapies for depression, PTSD, suicidality, and related conditions. Company updates center on NRX-100 preservative-free ketamine, NRX-101 as a D-cycloserine/lurasidone fixed-dose combination, FDA communications, generic-drug and new-drug application pathways, and clinical work involving treatment-resistant depression and suicidality.
Recurring news also covers commercial manufacturing preparations, drug-shortage context for ketamine injection, robotic-enabled transcranial magnetic stimulation initiatives through NRx Defense Systems, and interventional psychiatry activity through HOPE Therapeutics. Additional company developments include partnerships involving digital monitoring tools, leadership appointments, and research programs serving military, first-responder, and broader behavioral-health settings.
NRx Pharmaceuticals (Nasdaq: NRXP) reported Q1 2026 results and key pipeline advances. Net loss was $1.4 million, versus $5.5 million a year earlier, with operating loss of $4.7 million. Cash was $6.7 million on March 31, 2026, plus about $7 million raised post-quarter via an ATM facility.
NRx advanced its preservative-free ketamine ANDA toward an anticipated FDA decision in Q3 2026 and began commercial-scale manufacturing. It progressed NRX-101 in suicidal bipolar depression and as a TMS adjunct, expanded HOPE Therapeutics clinics, and moved toward acquiring Geneuro Phase 2 HERV-targeted assets.
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, will release its first quarter 2026 financial results before the market opens on Monday, May 18, 2026. Results and a live webcast for the accompanying 8:00 a.m. ET conference call will be available on the company’s investor relations website.
NRx Pharmaceuticals (Nasdaq: NRXP) received FDA clearance to start a randomized, double-blind phase 2/3 trial (MIND1) of NRX-101 (D-cycloserine/lurasidone) versus placebo as an adjunct to robotic-assisted or sham Transcranial Magnetic Stimulation (TMS) in adults with treatment-resistant major depressive disorder and suicidality.
The randomized portion will enroll 240 participants across a US academic hospital and three HOPE Therapeutics sites, with additional participants at two U.S. Military Treatment Facilities; IRB approvals and site details to follow.
NRx Pharmaceuticals (Nasdaq: NRXP) initiated a first commercial GMP manufacturing order for a preservative-free ketamine product ahead of expected GDUFA approval in Summer 2026. The program follows stability from 3 registration batches and a third-party GMP audit; pre-approval inspection readiness is reported.
Manufacturing uses a blow-fill-seal process with >10-fold throughput versus traditional sterile bottling. Company named Glenn Tyson as Chief Commercial Officer and cites ASHP shortage data (April 7, 2026) to underline domestic supply need.
NRx Pharmaceuticals (Nasdaq: NRXP) received a positive FDA Office of Generic Drugs Discipline Review Letter on its preservative-free ketamine ANDA, with requested changes labeled “Minor” and updates to prior stability data.
FDA leadership expressed support for completing review within the current cycle and the company is targeting Summer 2026 approval; NRx is also preparing an NDA to align ketamine labeling for depression and suicidality.
NRx Pharmaceuticals (Nasdaq:NRXP) welcomed a Presidential Executive Order signed April 18, 2026 to accelerate approvals of psychedelic medications for depression, PTSD, and suicidality.
The company has Fast Track designation and received FDA guidance ahead of an upcoming New Drug Application for NRX-100 (preservative-free ketamine) and has applied for a Commissioner’s National Priority Voucher to support that NDA.
NRx Pharmaceuticals (Nasdaq: NRXP) launched NRx Defense Systems, a Florida R&D subsidiary led by Dr. Dennis K. McBride to develop Combined Neuroplastic Therapy pairing D-cycloserine (NRX-101) with robotic-enabled Transcranial Magnetic Stimulation for military and first responder use.
The initiative partners with Zeta Surgical, whose AI neuronavigation received FDA 510(k) clearance in October 2025, and plans a prototype unveiling at the Clinical TMS Society meeting June 4-6, 2026. The company expects future R&D participation on a non-dilutive basis to current shareholders.
NRx Pharmaceuticals (Nasdaq: NRXP) named Glenn Tyson as its first Chief Commercial Officer on April 13, 2026. Tyson brings 25 years of commercial experience and clinical background to prepare for commercialization of a preservative‑free ketamine ANDA and a planned NDA to expand IV ketamine labeling to depression and suicidality.
The company also highlighted NRX‑101 (D‑Cycloserine) with prior Breakthrough Therapy recognition and plans to build market‑access, sales, and distribution ahead of potential launches.
NRx Pharmaceuticals (Nasdaq: NRXP) received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for its preservative-free ketamine Abbreviated New Drug Application. Label comments were limited to minor formatting; the company expects to submit a final label this month and anticipates a GDUFA decision in Summer 2026.
The company previously received a preliminary determination of bioequivalence. NRx says the product is U.S.-manufactured and could help augment domestic ketamine supply during current backorders; the labeling remains subject to final supervisory review.
Hope Therapeutics (Nasdaq: NRXP) announced a strategic partnership with Emobot to deploy its AI-powered Depression Thermometer across Hope’s interventional psychiatry clinics, integrating passive smartphone monitoring of facial expressions, vocal tone, and actigraphy to detect early relapse in TRD.
Preliminary pooled validation across three prospective studies showed concordance with MADRS (r=0.89) and PHQ-9 (r=0.83); Hope expects the tool to enable timely "recapture" interventions and improve patient outcomes.